Claims for Patent: 11,826,370

Summary for Patent: 11,826,370

Title:	Pharmaceutical compositions comprising meloxicam
Abstract:	Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Inventor(s):	Herriot Tabuteau
Assignee:	Axsome Therapeutics Inc
Application Number:	US18/062,729
Patent Claims:	1. A method of treating migraine, comprising orally administering a combination to a human being who is experiencing an acute attack of migraine pain; wherein the combination comprises meloxicam or a pharmaceutically acceptable salt thereof, and from about 8 mg to about 13 mg of rizatriptan, or a molar equivalent amount of a salt form of rizatriptan; wherein the combination is in a single dosage form; wherein the single dosage form is structured so that orally administering the single dosage form to healthy human subjects would result in a mean Tmax of meloxicam of 110 minutes or less, and an AUC0-24 of meloxicam of about 30 μg·hr/mL to about 50 μg·hr/mL; and wherein the human being experiences pain relief after the combination is orally administered. 2. The method of claim 1, wherein the human being is instructed to take the combination when the human being is experiencing an acute attack of migraine pain. 3. The method of claim 1, wherein the meloxicam is complexed with a sulfobutylether-β-cyclodextrin. 4. The method of claim 3, wherein the combination further comprises a bicarbonate. 5. The method of claim 1, wherein the combination further comprises a bicarbonate. 6. The method of claim 4, wherein 1) the complex of the meloxicam and the sulfobutylether-β-cyclodextrin, 2) the bicarbonate, and 3) the rizatriptan, are combined together in a monolayer tablet. 7. The method of claim 4, wherein the combination contains: about 10 mg of rizatriptan or a molar equivalent amount of a salt form of rizatriptan; about 20 mg of meloxicam or a molar equivalent of a salt form of meloxicam; and about 400 mg to about 600 mg of the bicarbonate. 8. The method of claim 7, wherein the bicarbonate is sodium bicarbonate. 9. The method of claim 7, wherein 1) the complex of the meloxicam and the sulfobutylether-β-cyclodextrin, 2) the bicarbonate, and 3) the rizatriptan, are combined together in a monolayer tablet. 10. The method of claim 4, wherein the bicarbonate is present in an amount that is effective to increase the dissolution rate of meloxicam. 11. The method of claim 4, wherein the bicarbonate is sodium bicarbonate. 12. The method of claim 5, wherein the bicarbonate is sodium bicarbonate. 13. The method of claim 1, wherein the meloxicam is in the free acid form. 14. The method of claim 1, wherein the rizatriptan is in a salt form.